Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut

Vilmarie Rodriguez, Peter M. Anderson, Barbara A. Trotz, Carola A.S. Arndt, Julia A. Allen, Shakila P. Khan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued.

Original languageEnglish (US)
Pages (from-to)212-215
Number of pages4
JournalPediatric Blood and Cancer
Volume49
Issue number2
DOIs
StatePublished - Aug 2007

Fingerprint

Graft vs Host Disease
Liver
Immunosuppressive Agents
Mycophenolic Acid
Tacrolimus
Therapeutics
Prednisone
Adrenal Cortex Hormones
Transplantation
daclizumab
Infliximab

Keywords

  • Daclizumab
  • Graft-versus-host disease
  • Immunosuppression
  • Infliximab

ASJC Scopus subject areas

  • Cancer Research
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. / Rodriguez, Vilmarie; Anderson, Peter M.; Trotz, Barbara A.; Arndt, Carola A.S.; Allen, Julia A.; Khan, Shakila P.

In: Pediatric Blood and Cancer, Vol. 49, No. 2, 08.2007, p. 212-215.

Research output: Contribution to journalArticle

Rodriguez, Vilmarie ; Anderson, Peter M. ; Trotz, Barbara A. ; Arndt, Carola A.S. ; Allen, Julia A. ; Khan, Shakila P. / Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. In: Pediatric Blood and Cancer. 2007 ; Vol. 49, No. 2. pp. 212-215.
@article{40e86d753bd642b59e996e8567f034c6,
title = "Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut",
abstract = "Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued.",
keywords = "Daclizumab, Graft-versus-host disease, Immunosuppression, Infliximab",
author = "Vilmarie Rodriguez and Anderson, {Peter M.} and Trotz, {Barbara A.} and Arndt, {Carola A.S.} and Allen, {Julia A.} and Khan, {Shakila P.}",
year = "2007",
month = "8",
doi = "10.1002/pbc.20648",
language = "English (US)",
volume = "49",
pages = "212--215",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut

AU - Rodriguez, Vilmarie

AU - Anderson, Peter M.

AU - Trotz, Barbara A.

AU - Arndt, Carola A.S.

AU - Allen, Julia A.

AU - Khan, Shakila P.

PY - 2007/8

Y1 - 2007/8

N2 - Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued.

AB - Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid-unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab-daclizumab regimen without toxicity and immunosuppressive therapy was discontinued.

KW - Daclizumab

KW - Graft-versus-host disease

KW - Immunosuppression

KW - Infliximab

UR - http://www.scopus.com/inward/record.url?scp=34447280617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447280617&partnerID=8YFLogxK

U2 - 10.1002/pbc.20648

DO - 10.1002/pbc.20648

M3 - Article

C2 - 16261610

AN - SCOPUS:34447280617

VL - 49

SP - 212

EP - 215

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 2

ER -